Navigation Links
TPI Reports Fiscal Year 2013 Financial Results
Date:9/27/2013

other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

Investors Contact: ir@tpi.asia
Web: http://www.tianyinpharma.com
Tel: +86-28-8551-6696 (Chengdu, China)
+86 134-36-550011 (China)

Address:

23rd Floor Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
ChinaTIANYIN PHARMACEUTICAL CO., INC.Consolidated Statements of OperationsFor the Years Ended June 30,20132012Sales$67,500,476$69,605,758Cost of sales41,496,81245,274,326Gross profit26,003,66424,331,432Operating expensesSelling expenses11,442,66410,672,817General and administrative expenses4,351,5924,255,528Research and development894,995860,081Total operating expenses16,689,25115,788,426Income from operations9,314,4138,543,006Other income (expenses):Interest income162,563209,037Interest expense(437,897)(331,334)Other income-189,268Total other income (expenses)(275,334)66,971Income before provision for income taxes9,039,0798,609,977Provision for income taxes2,423,9062,368,059Net income6,615,1736,241,918Less: Net loss attributable to noncontrolling interest(56,978)(116,772)Net income attributable to Tianyin Pharmaceutical Co., Inc.6,672,1516,358,690Basic earnings per share$0.23$0.22Diluted earnings per share$0.23$0.22Weighted average number of common shares outstanding:Basic29,341,69529,308,442Diluted29,341,69529,308,442 TIANYIN PHARMACEUTICAL CO., INC.Consolidated Statements of Comprehensive IncomeFor the Years Ended June 30,20132012Net income$6,615,173$6,241,918Other comprehensive incomeForeign currency translation adjustment2,083,0612,065,066Total other comprehensive income2,083,0612,065,066Total Comprehensive income8,698,2348,306,984Less: Comprehensive income attributable to the noncontrolling interest(51,749)(74,933)Comprehensive income attributable toTianyin Pharmaceutical Co., In
'/>"/>

SOURCE Tianyin Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
2. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
3. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
4. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
5. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
6. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
7. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
8. Omeros Reports Additional Positive Results from OMS824 Program
9. S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poors Factual Stock Reports
10. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
11. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Today FRC Action joined 19 pro-life groups in a letter sent to Food ... consideration for FDA approval that can cause abortions but is misleadingly labeled as an "emergency ... Tom McClusky ... the following comments: , , , ...
... INDIANAPOLIS , July 28 Eli Lilly and Company (NYSE: ... the Federal Circuit has upheld a prior ruling by the U.S. District Court ... invalid. , , , ... ruling by the U.S. Court of Appeals regarding Gemzar,s method-of-use patent. We continue ...
Cached Medicine Technology:FRC Action and Pro-Life Coalition Urge the FDA to Reject New Abortion-Causing Drug 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 3
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
(Date:7/9/2014)... Fox Chase Cancer Center paint a relatively optimistic picture ... cancers that have spread to the chest wall or ... into the skin, regardless of size and whether they ... III and called "locally advanced" tumors, suggesting that ... with poor survival. Locally advanced breast cancers of this ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... unveiled a new partnership with Axway to ... migration professionals and technologists to address the ... a timely and cost-effective manner.BELLEVUE, Wash., May ... healthcare electronic transactions simplification and systems interoperability, ...
... May 20 Industry-leading and renowned laparoscopic bariatric ... was recently selected by medical device manufacturers to ... the Tarrant County Region.Dr. Smith continues to lead ... procedures, known as SILS (Single Incision Laparoscopic Surgery), ...
... 20 Recondo Technology, a leading provider of ... announced that Harry Gambill and Jeff Fritz have ... http://www.newscom.com/cgi-bin/prnh/20090325/LA89162LOGO )Harry Gambill began with TransUnion in 1985 ... to 2007. During his 16-year tenure, TransUnion grew ...
... Lloyd H. Malchow Join Digirad Board of DirectorsPOWAY, Calif., ... ) today announced that it has named veteran healthcare ... its Board of Directors, effective immediately. The addition of ... total of seven members."Steve and Lloyd both have the ...
... how ARX,s CoSign® digital signatures fully integrate with Adobe LiveCycle® ES, ... processes. , ... San Francisco, CA (PRWEB) May 20, ... provider of the CoSign digital signature (standard electronic signature) solution ...
... Healthcommunities.com, Inc., announces the recent addition of a New ... neurologychannel.com. This newly updated section features important information about pain ... who suffer with tension headache, cluster headache, migraine, and other ... ...
Cached Medicine News:Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 3Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 4Health News:Dr. Adam Smith Chosen to Help Introduce No-Scar Surgical Weight-Loss Innovations 2Health News:Recondo Technology Announces Two New Board Members 2Health News:Digirad Names Two Veteran Healthcare Executives to Board 2Health News:Digirad Names Two Veteran Healthcare Executives to Board 3Health News:Digirad Names Two Veteran Healthcare Executives to Board 4Health News:SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution 2Health News:SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution 3Health News:Headache Sufferers Turn to Neurologychannel for Reliable Information about New Headache Treatments 2Health News:Headache Sufferers Turn to Neurologychannel for Reliable Information about New Headache Treatments 3
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
... a comprehensive, authoritative drug reference to ... overdose management, Canadian drug names, OTC ... drug references and tools is included ... (ED, PRIMARY CARE PLUS, CRC, RN, ...
... patients and health consumers from the trusted ... in MedMaster includes why the medication is ... side effects and warning signs of adverse ... information on what to do if a ...
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: